Meanwhile, Eli Lilly's clinical trial results for bimagrumab, a non-GLP weight loss treatment, showed a 10% weight loss, with Evercore ISI maintaining its In Line rating on the company. BMO Capital has reiterated its Outperform rating on Eli Lilly, highlighting developments in the company's metabolic portfolio, including advancements in its oral GLP-1 asset, naperiglipron. Truist Securities has also maintained a buy rating on Eli Lilly, focusing on the company's oral diabetes drug, orforglipron, despite some safety concerns about liver enzyme elevations. The firm believes these concerns may be overstated and views the drug's risk/benefit profile positively for Type 2 diabetes treatment. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.